Literature DB >> 8557826

Anti ICAM-1 (CD 54) monoclonal antibody reduces inflammatory changes in experimental bacterial meningitis.

J R Weber1, K Angstwurm, W Bürger, K M Einhäupl, U Dirnagl.   

Abstract

We investigated whether monoclonal antibodies directed against intracellular adhesion molecule 1 (ICAM-1 mAb) inhibit brain edema, increase of intracranial pressure (ICP), regional cerebral blood flow (rCBF) and recruitment of white blood cells (WBC) into the cerebrospinal fluid (CSF) in the rat model of the early phase of bacterial meningitis. Brain edema was assessed by brain water content determinations. rCBF measured by laser Doppler flowmetry and ICP were recorded continuously for 6 h after intracisternal challenge. Meningitis was induced with pneumococcal cell walls (PCW). Increase of ICP and brain water content were significantly inhibited (P <0.05) by intravenous treatment with ICAM-1 mAb (TM-8, 1 mg/kg). Furthermore, ICAM-1 mAb treatment profoundly attenuated (P <0.05) rCBF increase and WBC invasion into the CSF. These results suggest that the ICAM-1 pathway is critically involved in the early phase of bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8557826     DOI: 10.1016/0165-5728(95)00131-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

Review 1.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 2.  Development of adjunctive therapies for bacterial meningitis and lessons from knockout mice.

Authors:  Robert Paul; Uwe Koedel; Hans-Walter Pfister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Bacterial programmed cell death of cerebral endothelial cells involves dual death pathways.

Authors:  Daniela Bermpohl; Annett Halle; Dorette Freyer; Emilie Dagand; Johann S Braun; Ingo Bechmann; Nicolas W J Schröder; Joerg R Weber
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

Review 4.  The pneumococcus: epidemiology, microbiology, and pathogenesis.

Authors:  Birgitta Henriques-Normark; Elaine I Tuomanen
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

Review 5.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

6.  The polysaccharide fucoidin inhibits the antibiotic-induced inflammatory cascade in experimental pneumococcal meningitis.

Authors:  C Granert; J Raud; L Lindquist
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

7.  Lymphocytes modulate innate immune responses and neuronal damage in experimental meningitis.

Authors:  Olaf Hoffmann; Olga Rung; Josephin Held; Chotima Boettcher; Stefan Prokop; Werner Stenzel; Josef Priller
Journal:  Infect Immun       Date:  2014-10-27       Impact factor: 3.441

8.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 9.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

10.  Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningitis by activating NADPH oxidase.

Authors:  Robert Paul; Bianca Obermaier; Jessica Van Ziffle; Barbara Angele; Hans-Walter Pfister; Clifford A Lowell; Uwe Koedel
Journal:  J Leukoc Biol       Date:  2008-07-14       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.